Axogen Inc Cmn (AXGN) 7.64 $AXGN
AxoGen, Inc. Added to Russell 2000(R) Index
GlobeNewswire - Mon Jun 27, 6:00AM CDT
AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that the company has been added to the Russell 2000(R) Index, following the annual reconstitution of the Russell U.S. and global equity indexes.
AXGN: 7.64 (+0.41)
AxoGen, Inc.'s Avance(R) Nerve Graft Data to be Presented at 2016 Federation of European Societies for Surgery of the Hand International Congress
GlobeNewswire - Tue Jun 21, 6:00AM CDT
AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the acceptance of four presentations at the Congress of the Federation of European Societies for Surgery of the Hand (FESSH) related to use of Avance(R) Nerve Graft, including data from the RANGER(R) Registry. The data to be presented highlights that sensory and motor recovery outcomes from Avance(R) Nerve Graft repairs, in this group of patients, were found to compare favorably with autograft (nerve transplanted from the patient's own body). The data contained mixed nerve injuries up to 70 mm repaired with either Avance(R) Nerve Graft or autograft and both reported outcomes with greater than 85% meaningful recovery.
AXGN: 7.64 (+0.41)
AxoGen, Inc. First Quarter Revenue Increases 64% Over Prior Year to $8.1 Million
GlobeNewswire - Wed May 04, 3:10PM CDT
AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results for the first quarter ended March 31, 2016 and recent corporate developments.
AXGN: 7.64 (+0.41)
AxoGen (AXGN) Enters Overbought Territory
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:52AM CDT
AxoGen, Inc. (AXGN) has moved higher as of late, but there could definitely be trouble on the horizon for this company
AXGN: 7.64 (+0.41)
AxoGen, Inc. to Feature Nerve Repair Solutions at the American College of Oral and Maxillofacial Surgeons (ACOMS) Annual Scientific Conference and Exhibition
GlobeNewswire - Fri Apr 08, 5:59AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced its participation in the 2016 American College of Oral and Maxillofacial Surgeons (ACOMS) Annual Scientific Conference and Exhibition taking place in San Juan, Puerto Rico from April 9-12, 2016.
AXGN: 7.64 (+0.41)
AxoGen, Inc. Launches AcroVal™ Neurosensory & Motor Testing System
PRWeb - Wed Mar 30, 6:07AM CDT
AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the commercial release and first sale of AcroVal™ Neurosensory & Motor Testing System (NSMTS), a nerve function evaluation solution for surgeons and other allied health professionals to electronically measure, map, and monitor patients with peripheral nerve injuries and conditions. AcroVal™ is the Company's latest product introduction and will be complementary to the Company's portfolio of nerve repair products - Avance(R) Nerve Graft, AxoGuard(R) Nerve Connector and AxoGuard(R) Nerve Protector.
AXGN: 7.64 (+0.41)
AxoGen, Inc. Launches AcroVal(TM) Neurosensory & Motor Testing System
GlobeNewswire - Wed Mar 30, 6:05AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the commercial release and first sale of AcroVal(TM) Neurosensory & Motor Testing System (NSMTS), a nerve function evaluation solution for surgeons and other allied health professionals to electronically measure, map, and monitor patients with peripheral nerve injuries and conditions. AcroVal(TM) is the Company's latest product introduction and will be complementary to the Company's portfolio of nerve repair products - Avance(R) Nerve Graft, AxoGuard(R) Nerve Connector and AxoGuard(R) Nerve Protector.
AXGN: 7.64 (+0.41)
Kevin Leach Appointed Vice President of Marketing of AxoGen, Inc.
GlobeNewswire - Mon Mar 14, 6:21AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Kevin Leach as Vice President of Marketing effective March 14, 2016. Mr. Leach will report directly to Karen Zaderej, President and Chief Executive Officer and will be responsible for AxoGen's global marketing strategies and functions.
AXGN: 7.64 (+0.41)
AxoGen, Inc. to Participate at the 28th Annual ROTH Growth Conference
GlobeNewswire - Wed Mar 09, 6:09AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that Karen Zaderej, President and Chief Executive Officer, is scheduled to present at the 28th Annual ROTH Conference on Monday, March 14, 2016 at 4:30pm PT (7:30pm ET) in Dana Point, California.
AXGN: 7.64 (+0.41)
AxoGen, Inc. to Report Fourth Quarter and Full Year Results on February 29, 2016
PRWeb - Wed Feb 10, 6:04AM CST
AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the fourth quarter and full year ended December 31, 2015 on Monday, February 29, 2016 after the market closes.
AXGN: 7.64 (+0.41)
AxoGen, Inc. Avance(R) Nerve Graft Recipient to be Honored on Donate Life Rose Parade Float
PRWeb - Mon Dec 28, 3:31PM CST
AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that Matthew Jayroe, one of the thousands of patients who have had injured nerves repaired with AxoGen's Avance(R) Nerve Graft, will be honored as a recipient of donated nerve tissue.
AXGN: 7.64 (+0.41)
Equity Market Movement at a Glance - Research on AxoGen, Ampio Pharmaceuticals, Ultra Clean Holdings and Willbros Group
ACCESSWIRE - Mon Nov 23, 6:50AM CST
NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: AxoGen Inc. (NASDAQ: AXGN), Ampio Pharmaceuticals Inc. (NYSE: AMPE), Ultra Clean Holdings Inc. (NASDAQ: UCTT) and Willbros Group Inc. (NYSE: WG). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
AXGN: 7.64 (+0.41), WG: 2.64 (+0.15), AMPE: 1.09 (-0.06), UCTT: 5.64 (-0.01)
AxoGen Inc. Third Quarter Revenue Exceeds $8 Million
GlobeNewswire - Thu Nov 05, 3:17PM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, reported record revenue of $8.15 million in the third quarter. The record quarterly result represents the first time in the Company's history that quarterly revenue surpassed $8 million. In addition, management raised revenue guidance for the full year to reflect the strong year-to-date growth.
AXGN: 7.64 (+0.41)
PDL BioPharma Announces Third Quarter 2015 Financial Results
PR Newswire - Wed Nov 04, 3:03PM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the third quarter and nine months ended September 30, 2015.
ACRX: 2.98 (+0.14), AXGN: 7.64 (+0.41), DEPO: 18.77 (+0.01), ARIA: 7.51 (+0.17), PDLI: 3.28 (+0.10)
Leading 200 Global Medical Devices/Technology/Supplies Companies that have Launched New Products
M2 - Thu Oct 22, 2:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrcc44/global_new) has announced the addition of the "Global New Products Medical Devices/Technology/Supplies 200 " report to their offering. The newly launched report identifies 200 medical devices/technology/supplies companies globally that have launched New Products recently, and covers news of such 200 companies as well as provides details about new products launched by these companies. Medical scientists and physicians are constantly conducting research and testing new procedures to help prevent, diagnose, and cure diseases as well as developing new drugs and new medical products/devices/technology that can lessen symptoms or treat ailments. Profound insight into the companies' value drivers of innovation can release additional, untapped potential. From small innovations like adhesive bandages and ankle braces, to larger, more complex technologies like MRI machines, artificial organs, and robotic prosthetic limbs, technology has undoubtedly made an incredible impact on medicine. Highlights - Leading 200 global medical devices/technology/supplies companies that have launched new products recently covered - Provides detailed summary on new product categories - Summary of other news besides product launch for such companies - Important M&A and alliances of global medical devices/technology/supplies companies with new products - International presence of global medical devices/technology/supplies companies with new products Key Topics Covered: 1: Key New Products Launched by Global Medical Devices/Technology/Supplies Companies 2: Analysis of Global Medical Devices/Technology/Supplies Companies with New Products by Various Attributes 3: Key News of Global Medical Devices/Technology/Supplies Companies with New Products for Year 2014-15 4: Key Alliances of Global Medical Devices/Technology/Supplies Companies with New Products 5: International Presence of Global Medical Devices/Technology/Supplies Companies with New Products 6: Mergers and Acquisitions of Global Medical Devices/Technology/Supplies Companies with New Products Companies Mentioned - Partial List - 3D Systems Corporation - Accuray Inc - Acelity L.P. Inc - Affymetrix, Inc. - Aurora Spine Corp - Avita Medical Limited - AxoGen Inc. - Calgary Scientific Inc. - Cardica, Inc - Cardiocomm Solutions? - Carl Zeiss Meditec AG - Cellavision AB - CloudTag Inc - Cochlear Limited - Cogentix Medical Inc. - Coherent Incorporated - Electromed, Incorporation - Elekta publ AB - Encision Inc - Endologix, Inc. - Entellus Medical Inc - Exactech, Inc. - Exiqon AS - FEI Company - Fisher & Paykel Healthcare Corporation Limited - Fluidigm Corp. - Foundation Medicine Inc. - Fresenius Medical Care AG & Co. KGaA For more information visit http://www.researchandmarkets.com/research/qrcc44/global_new
AXGN: 7.64 (+0.41), DDD: 14.12 (+0.66), ARAY: 5.19 (+0.29), ELGX: 14.24 (+0.54), AFFX: 14.01 (+0.02), FEIC: 106.78 (-0.23), CGNT: 1.06 (+0.01), FMI: 21.82 (+0.68), FLDM: 9.64 (+0.54), ENTL: 18.03 (+0.09), CRDC: 2.35 (-0.15), EXAC: 27.12 (+0.51), COHR: 93.01 (+2.60)
AxoGen, Inc. to Report Third Quarter Results on November 5, 2015
GlobeNewswire - Fri Oct 16, 6:04AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the third quarter and nine months ended September 30, 2015 on Thursday, November 5, 2015 after the market closes.
AXGN: 7.64 (+0.41)
AxoGen, Inc. Added to Russell 2000(R) Index
GlobeNewswire - Mon Jun 27, 6:00AM CDT
AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that the company has been added to the Russell 2000(R) Index, following the annual reconstitution of the Russell U.S. and global equity indexes.
AXGN: 7.64 (+0.41)
AxoGen, Inc.'s Avance(R) Nerve Graft Data to be Presented at 2016 Federation of European Societies for Surgery of the Hand International Congress
GlobeNewswire - Tue Jun 21, 6:00AM CDT
AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the acceptance of four presentations at the Congress of the Federation of European Societies for Surgery of the Hand (FESSH) related to use of Avance(R) Nerve Graft, including data from the RANGER(R) Registry. The data to be presented highlights that sensory and motor recovery outcomes from Avance(R) Nerve Graft repairs, in this group of patients, were found to compare favorably with autograft (nerve transplanted from the patient's own body). The data contained mixed nerve injuries up to 70 mm repaired with either Avance(R) Nerve Graft or autograft and both reported outcomes with greater than 85% meaningful recovery.
AXGN: 7.64 (+0.41)
AxoGen, Inc. First Quarter Revenue Increases 64% Over Prior Year to $8.1 Million
GlobeNewswire - Wed May 04, 3:10PM CDT
AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results for the first quarter ended March 31, 2016 and recent corporate developments.
AXGN: 7.64 (+0.41)
AxoGen (AXGN) Enters Overbought Territory
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:52AM CDT
AxoGen, Inc. (AXGN) has moved higher as of late, but there could definitely be trouble on the horizon for this company
AXGN: 7.64 (+0.41)
AxoGen, Inc. to Feature Nerve Repair Solutions at the American College of Oral and Maxillofacial Surgeons (ACOMS) Annual Scientific Conference and Exhibition
GlobeNewswire - Fri Apr 08, 5:59AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced its participation in the 2016 American College of Oral and Maxillofacial Surgeons (ACOMS) Annual Scientific Conference and Exhibition taking place in San Juan, Puerto Rico from April 9-12, 2016.
AXGN: 7.64 (+0.41)
AxoGen, Inc. Launches AcroVal™ Neurosensory & Motor Testing System
PRWeb - Wed Mar 30, 6:07AM CDT
AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the commercial release and first sale of AcroVal™ Neurosensory & Motor Testing System (NSMTS), a nerve function evaluation solution for surgeons and other allied health professionals to electronically measure, map, and monitor patients with peripheral nerve injuries and conditions. AcroVal™ is the Company's latest product introduction and will be complementary to the Company's portfolio of nerve repair products - Avance(R) Nerve Graft, AxoGuard(R) Nerve Connector and AxoGuard(R) Nerve Protector.
AXGN: 7.64 (+0.41)
AxoGen, Inc. Launches AcroVal(TM) Neurosensory & Motor Testing System
GlobeNewswire - Wed Mar 30, 6:05AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the commercial release and first sale of AcroVal(TM) Neurosensory & Motor Testing System (NSMTS), a nerve function evaluation solution for surgeons and other allied health professionals to electronically measure, map, and monitor patients with peripheral nerve injuries and conditions. AcroVal(TM) is the Company's latest product introduction and will be complementary to the Company's portfolio of nerve repair products - Avance(R) Nerve Graft, AxoGuard(R) Nerve Connector and AxoGuard(R) Nerve Protector.
AXGN: 7.64 (+0.41)
Kevin Leach Appointed Vice President of Marketing of AxoGen, Inc.
GlobeNewswire - Mon Mar 14, 6:21AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Kevin Leach as Vice President of Marketing effective March 14, 2016. Mr. Leach will report directly to Karen Zaderej, President and Chief Executive Officer and will be responsible for AxoGen's global marketing strategies and functions.
AXGN: 7.64 (+0.41)
AxoGen, Inc. to Participate at the 28th Annual ROTH Growth Conference
GlobeNewswire - Wed Mar 09, 6:09AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that Karen Zaderej, President and Chief Executive Officer, is scheduled to present at the 28th Annual ROTH Conference on Monday, March 14, 2016 at 4:30pm PT (7:30pm ET) in Dana Point, California.
AXGN: 7.64 (+0.41)
AxoGen, Inc. to Report Fourth Quarter and Full Year Results on February 29, 2016
PRWeb - Wed Feb 10, 6:04AM CST
AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the fourth quarter and full year ended December 31, 2015 on Monday, February 29, 2016 after the market closes.
AXGN: 7.64 (+0.41)
AxoGen, Inc. Avance(R) Nerve Graft Recipient to be Honored on Donate Life Rose Parade Float
PRWeb - Mon Dec 28, 3:31PM CST
AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that Matthew Jayroe, one of the thousands of patients who have had injured nerves repaired with AxoGen's Avance(R) Nerve Graft, will be honored as a recipient of donated nerve tissue.
AXGN: 7.64 (+0.41)
Equity Market Movement at a Glance - Research on AxoGen, Ampio Pharmaceuticals, Ultra Clean Holdings and Willbros Group
ACCESSWIRE - Mon Nov 23, 6:50AM CST
NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: AxoGen Inc. (NASDAQ: AXGN), Ampio Pharmaceuticals Inc. (NYSE: AMPE), Ultra Clean Holdings Inc. (NASDAQ: UCTT) and Willbros Group Inc. (NYSE: WG). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
AXGN: 7.64 (+0.41), WG: 2.64 (+0.15), AMPE: 1.09 (-0.06), UCTT: 5.64 (-0.01)
AxoGen Inc. Third Quarter Revenue Exceeds $8 Million
GlobeNewswire - Thu Nov 05, 3:17PM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, reported record revenue of $8.15 million in the third quarter. The record quarterly result represents the first time in the Company's history that quarterly revenue surpassed $8 million. In addition, management raised revenue guidance for the full year to reflect the strong year-to-date growth.
AXGN: 7.64 (+0.41)
PDL BioPharma Announces Third Quarter 2015 Financial Results
PR Newswire - Wed Nov 04, 3:03PM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the third quarter and nine months ended September 30, 2015.
ACRX: 2.98 (+0.14), AXGN: 7.64 (+0.41), DEPO: 18.77 (+0.01), ARIA: 7.51 (+0.17), PDLI: 3.28 (+0.10)
Leading 200 Global Medical Devices/Technology/Supplies Companies that have Launched New Products
M2 - Thu Oct 22, 2:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrcc44/global_new) has announced the addition of the "Global New Products Medical Devices/Technology/Supplies 200 " report to their offering. The newly launched report identifies 200 medical devices/technology/supplies companies globally that have launched New Products recently, and covers news of such 200 companies as well as provides details about new products launched by these companies. Medical scientists and physicians are constantly conducting research and testing new procedures to help prevent, diagnose, and cure diseases as well as developing new drugs and new medical products/devices/technology that can lessen symptoms or treat ailments. Profound insight into the companies' value drivers of innovation can release additional, untapped potential. From small innovations like adhesive bandages and ankle braces, to larger, more complex technologies like MRI machines, artificial organs, and robotic prosthetic limbs, technology has undoubtedly made an incredible impact on medicine. Highlights - Leading 200 global medical devices/technology/supplies companies that have launched new products recently covered - Provides detailed summary on new product categories - Summary of other news besides product launch for such companies - Important M&A and alliances of global medical devices/technology/supplies companies with new products - International presence of global medical devices/technology/supplies companies with new products Key Topics Covered: 1: Key New Products Launched by Global Medical Devices/Technology/Supplies Companies 2: Analysis of Global Medical Devices/Technology/Supplies Companies with New Products by Various Attributes 3: Key News of Global Medical Devices/Technology/Supplies Companies with New Products for Year 2014-15 4: Key Alliances of Global Medical Devices/Technology/Supplies Companies with New Products 5: International Presence of Global Medical Devices/Technology/Supplies Companies with New Products 6: Mergers and Acquisitions of Global Medical Devices/Technology/Supplies Companies with New Products Companies Mentioned - Partial List - 3D Systems Corporation - Accuray Inc - Acelity L.P. Inc - Affymetrix, Inc. - Aurora Spine Corp - Avita Medical Limited - AxoGen Inc. - Calgary Scientific Inc. - Cardica, Inc - Cardiocomm Solutions? - Carl Zeiss Meditec AG - Cellavision AB - CloudTag Inc - Cochlear Limited - Cogentix Medical Inc. - Coherent Incorporated - Electromed, Incorporation - Elekta publ AB - Encision Inc - Endologix, Inc. - Entellus Medical Inc - Exactech, Inc. - Exiqon AS - FEI Company - Fisher & Paykel Healthcare Corporation Limited - Fluidigm Corp. - Foundation Medicine Inc. - Fresenius Medical Care AG & Co. KGaA For more information visit http://www.researchandmarkets.com/research/qrcc44/global_new
AXGN: 7.64 (+0.41), DDD: 14.12 (+0.66), ARAY: 5.19 (+0.29), ELGX: 14.24 (+0.54), AFFX: 14.01 (+0.02), FEIC: 106.78 (-0.23), CGNT: 1.06 (+0.01), FMI: 21.82 (+0.68), FLDM: 9.64 (+0.54), ENTL: 18.03 (+0.09), CRDC: 2.35 (-0.15), EXAC: 27.12 (+0.51), COHR: 93.01 (+2.60)
AxoGen, Inc. to Report Third Quarter Results on November 5, 2015
GlobeNewswire - Fri Oct 16, 6:04AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the third quarter and nine months ended September 30, 2015 on Thursday, November 5, 2015 after the market closes.
AXGN: 7.64 (+0.41)
